Adnkronos "The Emerald-3 study represents the latest development in combination therapies" for the treatment of hepatocellular carcinoma (HCC). "It is a study that combines immunotherapy and an anti-angiogenic drug, combining them with the standard treatment for intermediate-stage HCC, namely chemoembolization, an effective treatment for intermediate-stage HCC, capable of ensuring disease control in over 80% of cases.
However, unfortunately, the disease persists and tends to progress over time. Combining immunotherapy means combining locoregional control with systemic control, making the therapeutic response more lasting and profound,” said Sherrie Bhoori, hepatologist, Hepato-Gastro-Pancreatic Oncology and Liver Transplant Unit at the Fondazione IRCCS Istituto Nazionale Tumori in Milan, during the media tutorial on new frontiers in liver cancer treatment, promoted by AstraZeneca in Milan.
https://www.youtube.com/watch?v=16YlL3Xi9rc